Development and validation of a nomogram to predict survival for advanced male breast cancer

Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Sur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Andrologia 2022-09, Vol.54 (8), p.e14479-n/a
Hauptverfasser: Zhang, Li‐Ping, Lin, Hui, Wang, Ai‐Jing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 8
container_start_page e14479
container_title Andrologia
container_volume 54
creator Zhang, Li‐Ping
Lin, Hui
Wang, Ai‐Jing
description Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.
doi_str_mv 10.1111/and.14479
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2671264854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696933897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</originalsourceid><addsrcrecordid>eNp10E1r3DAQBmBRUpol3UP_QBDkkh6cSNaXdVyyTVJY2kt7K5ixNA4OtrWR7A3776vNJjkUOpcRw8OLeAn5wtkVz3MNo7_iUhr7gSy4FLZgpSlPyIIJJgqptD0ly5QeWR6pjJHyEzkVSvPKKrsgf9a4wz5sBxwnmqPoDvrOw9SFkYaWAh3DEB4iDHQKdBvRd26iaY67LkPahkjB72B06OkAPdImIqSJusMpfiYfW-gTLl_3Gfl9--3XzX2x-Xn3_Wa1KZyoKltULau4kg14b0otTH5YppvGytJLq8GBNdgayZ0C1IY5zhjHfGUWmFIozsjlMXcbw9OMaaqHLjnsexgxzKkuteGllpWSmV78Qx_DHMf8u6ystkJU1mT19ahcDClFbOtt7AaI-5qz-tB6nauqX1rP9vw1cW4G9O_yreMMro_guetx__-kevVjfYz8C3fliu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696933897</pqid></control><display><type>article</type><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</creator><creatorcontrib>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</creatorcontrib><description>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</description><identifier>ISSN: 0303-4569</identifier><identifier>EISSN: 1439-0272</identifier><identifier>DOI: 10.1111/and.14479</identifier><identifier>PMID: 35618959</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>advanced male breast cancer ; Breast cancer ; Epidemiology ; Mens health ; nomogram ; Nomograms ; Prediction models ; prognosis ; Rare diseases ; Survival</subject><ispartof>Andrologia, 2022-09, Vol.54 (8), p.e14479-n/a</ispartof><rights>2022 Wiley‐VCH GmbH.</rights><rights>2022 Wiley-VCH GmbH.</rights><rights>2022 Wiley‐VCH GmbH</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</citedby><cites>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</cites><orcidid>0000-0001-7198-6418</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fand.14479$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fand.14479$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35618959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Li‐Ping</creatorcontrib><creatorcontrib>Lin, Hui</creatorcontrib><creatorcontrib>Wang, Ai‐Jing</creatorcontrib><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><title>Andrologia</title><addtitle>Andrologia</addtitle><description>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</description><subject>advanced male breast cancer</subject><subject>Breast cancer</subject><subject>Epidemiology</subject><subject>Mens health</subject><subject>nomogram</subject><subject>Nomograms</subject><subject>Prediction models</subject><subject>prognosis</subject><subject>Rare diseases</subject><subject>Survival</subject><issn>0303-4569</issn><issn>1439-0272</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10E1r3DAQBmBRUpol3UP_QBDkkh6cSNaXdVyyTVJY2kt7K5ixNA4OtrWR7A3776vNJjkUOpcRw8OLeAn5wtkVz3MNo7_iUhr7gSy4FLZgpSlPyIIJJgqptD0ly5QeWR6pjJHyEzkVSvPKKrsgf9a4wz5sBxwnmqPoDvrOw9SFkYaWAh3DEB4iDHQKdBvRd26iaY67LkPahkjB72B06OkAPdImIqSJusMpfiYfW-gTLl_3Gfl9--3XzX2x-Xn3_Wa1KZyoKltULau4kg14b0otTH5YppvGytJLq8GBNdgayZ0C1IY5zhjHfGUWmFIozsjlMXcbw9OMaaqHLjnsexgxzKkuteGllpWSmV78Qx_DHMf8u6ystkJU1mT19ahcDClFbOtt7AaI-5qz-tB6nauqX1rP9vw1cW4G9O_yreMMro_guetx__-kevVjfYz8C3fliu4</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Zhang, Li‐Ping</creator><creator>Lin, Hui</creator><creator>Wang, Ai‐Jing</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7198-6418</orcidid></search><sort><creationdate>202209</creationdate><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><author>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>advanced male breast cancer</topic><topic>Breast cancer</topic><topic>Epidemiology</topic><topic>Mens health</topic><topic>nomogram</topic><topic>Nomograms</topic><topic>Prediction models</topic><topic>prognosis</topic><topic>Rare diseases</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Li‐Ping</creatorcontrib><creatorcontrib>Lin, Hui</creatorcontrib><creatorcontrib>Wang, Ai‐Jing</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Andrologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Li‐Ping</au><au>Lin, Hui</au><au>Wang, Ai‐Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of a nomogram to predict survival for advanced male breast cancer</atitle><jtitle>Andrologia</jtitle><addtitle>Andrologia</addtitle><date>2022-09</date><risdate>2022</risdate><volume>54</volume><issue>8</issue><spage>e14479</spage><epage>n/a</epage><pages>e14479-n/a</pages><issn>0303-4569</issn><eissn>1439-0272</eissn><abstract>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35618959</pmid><doi>10.1111/and.14479</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7198-6418</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0303-4569
ispartof Andrologia, 2022-09, Vol.54 (8), p.e14479-n/a
issn 0303-4569
1439-0272
language eng
recordid cdi_proquest_miscellaneous_2671264854
source Wiley Online Library Journals Frontfile Complete
subjects advanced male breast cancer
Breast cancer
Epidemiology
Mens health
nomogram
Nomograms
Prediction models
prognosis
Rare diseases
Survival
title Development and validation of a nomogram to predict survival for advanced male breast cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A59%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20a%20nomogram%20to%20predict%20survival%20for%20advanced%20male%20breast%20cancer&rft.jtitle=Andrologia&rft.au=Zhang,%20Li%E2%80%90Ping&rft.date=2022-09&rft.volume=54&rft.issue=8&rft.spage=e14479&rft.epage=n/a&rft.pages=e14479-n/a&rft.issn=0303-4569&rft.eissn=1439-0272&rft_id=info:doi/10.1111/and.14479&rft_dat=%3Cproquest_cross%3E2696933897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696933897&rft_id=info:pmid/35618959&rfr_iscdi=true